OKYO Pharma Announces Chairman and Founder Acquires Shares
OKYO Pharma (NASDAQ: OKYO) announced that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 82,018 ordinary shares on NASDAQ on November 21, 2025.
The purchase increases the Chairman's total holding to 10,464,695 shares. The company is developing urcosimod for neuropathic corneal pain (NCP), an ocular condition without an FDA-approved therapy.
OKYO Pharma (NASDAQ: OKYO) ha annunciato che Panetta Partners Limited, una società in cui l'Amministratore Delegato Gabriele Cerrone detiene un interesse beneficiario, ha acquisito 82.018 azioni ordinarie su NASDAQ il 21 novembre 2025.
L'acquisto aumenta la partecipazione totale del Presidente a 10.464.695 azioni. L'azienda sta sviluppando l'urcosimod per il dolore neuropatico oculare (NCP), una condizione oculare per la quale non esiste una terapia approvata dalla FDA.
OKYO Pharma (NASDAQ: OKYO) anunció que Panetta Partners Limited, una entidad en la que el presidente ejecutivo Gabriele Cerrone posee un interés beneficiario, adquirió 82,018 acciones ordinarias en NASDAQ el 21 de noviembre de 2025.
La compra eleva la participación total del Presidente a 10,464,695 acciones. La compañía está desarrollando urcosimod para el dolor neuropático ocular (NCP), una condición ocular para la cual no existe una terapia aprobada por la FDA.
OKYO Pharma (NASDAQ: OKYO)는 이사 회장 겸 최고경영자 Gabriele Cerrone가 유익한 이해관계를 가진 Panetta Partners Limited가 2025년 11월 21일 NASDAQ에서 82,018주 보통주를 취득했다고 발표했습니다.
매입으로 회장의 총 보유 주식은 10,464,695주로 증가합니다. 회사는 FDA 승인을 받은 치료제가 없는 눈 질환인 신경병성 각막통(NCP)을 위해 우르코시모드를 개발하고 있습니다.
OKYO Pharma (NASDAQ: OKYO) a annoncé que Panetta Partners Limited, une entité dans laquelle le président exécutif Gabriele Cerrone détient un intérêt bénéficiaire, a acquis 82 018 actions ordinaires sur le NASDAQ le 21 novembre 2025.
cet achat porte la participation totale du président à 10 464 695 actions. La société développe l'urcosimod pour la douleur neuropathique oculaire (NPO), une affection oculaire sans thérapie approuvée par la FDA.
OKYO Pharma (NASDAQ: OKYO) gab bekannt, dass Panetta Partners Limited, eine Gesellschaft, an der der ausführende Vorsitzende Gabriele Cerrone einen wirtschaftlichen Anteil hält, am 21. November 2025 82.018 Stammaktien an der NASDAQ erworben hat.
Der Kauf erhöht die Gesamtbeteiligung des Vorsitzenden auf 10.464.695 Aktien. Das Unternehmen entwickelt Urcosimod zur neuropathischen Hornhaut-Schmerzen (NCP), eine Augenkrankheit, für die es keine FDA-zugelassene Therapie gibt.
OKYO Pharma (بورصة ناسداك: OKYO) أعلنت أن Panetta Partners Limited، وهي كيان يملك الرئيس التنفيذي جابرلي سيروني مصلحة فائدة، قد اشترت 82,018 سهماً عاديّاً في ناسداك يوم 21 نوفمبر 2025.
الشراء يرفع الحيازة الإجمالية للرئيس إلى 10,464,695 سهماً. الشركة طورت urcosimod لآلام القرنية العصبية (NCP)، وهي حالة عين لا يوجد لها علاج معتمد من FDA.
- Insider purchase of 82,018 shares by Chairman
- Total holding increased to 10,464,695 shares
- Leadership signal could indicate confidence in urcosimod development
- None.
LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 82,018 of the Company’s ordinary shares on NASDAQ, bringing his total holding to 10,464,695 shares.
About Urcosimod (Formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating ocular diseases. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the efficacy of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints in a 240-patient completed Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and just completed a randomized, placebo-controlled, double-masked Phase 2 trial of urcosimod to treat neuropathic corneal pain.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. A Phase 2 trial of urcosimod to treat neuropathic corneal pain patients was just completed by OKYO.
For further information, please visit www.okyopharma.com.
Inquiries:
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ
What did OKYO Pharma announce on November 21, 2025 regarding insider buying?
Who owns the shares bought in the OKYO Pharma insider purchase (NASDAQ: OKYO)?
How many OKYO shares does Gabriele Cerrone hold after the November 21, 2025 purchase?
Does the OKYO insider purchase affect the development of urcosimod for NCP?
What does the OKYO (NASDAQ: OKYO) insider buy mean for investors short-term?
Where was the OKYO Pharma insider transaction executed and when was it announced?
